Investigational New Drugs

, 27:579 | Cite as

Trastuzumab-induced CCL20 and interleukin-8 mRNA in human whole blood ex vivo

  • Setsuo Hasegawa
  • Hideaki Kato
  • Hiroki Yamaguchi
  • Masafumi Yohda
  • Kazuhiko Obara
  • Hiroshi Izutsu
  • Mieko Ogura
  • Masato MitsuhashiEmail author


Heparinized human whole blood from 16 adult volunteers was stimulated with achievable blood concentrations of trastuzumab and rituximab at 37°C for 4 h, then CCL20, IL8, and β-actin mRNA were quantified. The fold increase of β-actin was all less than 1.5, and heat aggregated IgG induced both IL8 and CCL20 mRNA in all cases, suggesting that the assay was performed appropriately. Rituximab reduced the levels of CCL20 mRNA in approximately 1/3 of subjects, whereas 50 μg/ml trastuzumab induced IL8 and CCL20 mRNA in more than half of subjects. Although the results do not directly indicate the toxicity of antibody medicines, the individual variation found under physiological ex vivo condition will be an interesting clinical research model for drug safety analysis.


Trastuzumab Antibody medicine Inflammatory cytokine mRNA expression CCL20 IL8 



We would like to thank Ms. Ai Kobayashi and Ms. Sayaka Kimura (Sekino Clinical Pharmacology Clinic) for technical assistant during blood collection and stimulations, Dr. Jifan Li, Mr. Taku Murakami, and Mr. Toshit Sen (Hitachi Chemical Research Center) for technical assistant during HPLC analyses, and Dr. Terumasa Miyamoto (professor emeritus, Tokyo University) for his critical review of the manuscript.


  1. 1.
    Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028. doi: 10.1056/NEJMoa063842 CrossRefPubMedGoogle Scholar
  2. 2.
    Mitsuhashi M (2007) Ex vivo simulation of drug action: quantification of drug-induced mRNA as a bridge between preclinical and clinical trials. Clin Chem 53:148–149. doi: 10.1373/clinchem.2006.080473 CrossRefPubMedGoogle Scholar
  3. 3.
    Mitsuhashi M, Endo K, Obara K et al (2008) Quantification of drug-induced mRNA in human whole blood ex vivo. Clin Med Blood Disord 1:1–11Google Scholar
  4. 4.
    Mitsuhashi M, Endo K, Obara K et al (2008) Ex vivo simulation of the action of antileukemia drugs by measuring apoptosis-related mRNA in blood. Clin Chem 54:673–681. doi: 10.1373/clinchem.2007.091975 CrossRefPubMedGoogle Scholar
  5. 5.
    Mitsuhashi M, Ogura M, Endo K et al (2008) Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development. Pharm Res 25:1116–1124. doi: 10.1007/s11095-007-9510-2 CrossRefPubMedGoogle Scholar
  6. 6.
    Mitsuhashi M, Endo K, Shinagawa A (2006) Quantification of mRNA in whole blood by assessing recovery of RNA and efficiency of cDNA synthesis. Clin Chem 52:634–642. doi: 10.1373/clinchem.2005.048983 CrossRefPubMedGoogle Scholar
  7. 7.
    Mitsuhashi M, Targan SR (2008) Ex vivo simulation of IgG Fc and T-cell receptor functions: an application to inflammatory bowel disease. Inflamm Bowel Dis 14:1061–1067. doi: 10.1002/ibd.20428 CrossRefPubMedGoogle Scholar
  8. 8.
    Ostreiko KK, Tumanova IA, Sykulev YK (1987) Production and characterization of heat-aggregated IgG complexes with pre-determined molecular masses: light-scattering study. Immunol Lett 15:311–316. doi: 10.1016/0165-2478(87)90134-9 CrossRefPubMedGoogle Scholar
  9. 9.
    Morrison TB, Weis JJ, Wittwer CT (1998) Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24:954–962PubMedGoogle Scholar
  10. 10.
    Baggiolini M, Clark-Lewis I (1992) Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 307:97–101. doi: 10.1016/0014-5793(92)80909-Z CrossRefPubMedGoogle Scholar
  11. 11.
    Hieshima K, Imai T, Opdenakker G et al (1997) Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 272:5846–5853. doi: 10.1074/jbc.272.9.5846 CrossRefPubMedGoogle Scholar
  12. 12.
    Lub-de Hooge MN, Kosterink JG, Perik PJ et al (2004) Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 143:99–106. doi: 10.1038/sj.bjp.0705915 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Setsuo Hasegawa
    • 1
  • Hideaki Kato
    • 1
  • Hiroki Yamaguchi
    • 2
  • Masafumi Yohda
    • 3
  • Kazuhiko Obara
    • 4
  • Hiroshi Izutsu
    • 4
  • Mieko Ogura
    • 5
  • Masato Mitsuhashi
    • 5
    Email author
  1. 1.Sekino Clinical Pharmacology ClinicTokyoJapan
  2. 2.Department of 3rd Internal Medicine (Hematology & Oncology)Nippon Medical SchoolTokyoJapan
  3. 3.Department of Biotechnology and Life Science, Graduate School of TechnologyTokyo University of Agriculture and TechnologyTokyoJapan
  4. 4.Hitachi Chemical Co., Ltd.HitachiJapan
  5. 5.Hitachi Chemical Research Center, Inc.IrvineUSA

Personalised recommendations